Search

James K. McCloskey, Andreas Hochhaus, Lori J. Maness, Michael W. Deininger, Vickie Lu, Tomasz Sacha, Christine Rojas, Charles Chuah, Moshe Talpaz, Beatriz Moiraghi, Tracey Hall, Anna G. Turkina, Jorge E. Cortes, Maria Undurraga Sutton, Hugues de Lavallade, Gianantonio Rosti, Christopher Arthur, Elza Lomaia, Michael J. Mauro, Charles A. Schiffer, Shouryadeep Srivastava, Jane F. Apperley, Carolina Pavlovsky, Jeffrey H. Lipton, Philippe Rousselot, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre Hospitalier de Versailles André Mignot (CHV), Bristol-Myers Squibb, BMS, Pfizer, Astellas Pharma US, APUS, Novartis, Takeda Pharmaceuticals U.S.A., TPUSA, Jazz Pharmaceuticals, Daiichi-Sankyo, Sun Pharma, Conflict-of-interest disclosure: J.C. has been a consultant to and received research funding from Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Astellas, Novartis, Pfizer, Takeda, and BioPath Holdings, has received research funding from Sun Pharma, Telios, Arog, Merus, and Immunogen, has held membership on the board of directors or advisory committee of BioPath Holdings, and has been a consultant to Amphivena Therapeutics and BiolineRx. J.A. has received honoraria and research funding and is on the speakers bureaus of Incyte and Pfizer, and has received honoraria and served on the speakers bureaus of Bristol Myers Squibb and Novartis. E.L. has served on the speakers bureaus of Novartis and Pfizer, and has received travel and accommodation reimbursement from Novartis, Pfizer, and Bristol Myers Squibb. B.M. has served on the speakers bureaus of Novartis, Pfizer, and Takeda. M.U.S. has served on the advisory boards of AbbVie, Janssen, Novartis, Pfizer, and Roche and on the speakers bureaus of Janssen, Novartis, and Pfizer. C.C. has received honoraria from Novartis and Korea Otsuka Pharmaceutical, received honoraria and research funding from Bristol Myers Squibb, and received travel reimbursement and research funding from Pfizer. T.S. has been a consultant to, has received honoraria from, and has served on the speakers bureaus of Bristol Myers Squibb, Novartis, Pfizer, and Incyte, and has been a consultant to and received honoraria from Adamed. J.H.L. has been a consultant to and has received research funding from Bristol Myers Squibb, Ariad, Pfizer, and Novartis. C.A.S. has been a consultant to Bristol Myers Squibb and Novartis, and has received research funding from Takeda. A.H. has received honoraria and research funding from Bristol Myers Squibb, Novartis, and Pfizer, research funding from Incyte and Merck Sharp & Dohme, and honoraria from Takeda. P.R. has been a consultant to and has received funding from Incyte and Pfizer, and has been a consultant to Bristol Myers Squibb, Novartis, and Takeda. G.R. has received research funding from and served on the speakers bureau for Pfizer, and has served on the speakers bureaus of Bristol Myers Squibb, Incyte, and Novartis. H. de L. has received honoraria and research funding from Bristol Myers Squibb and Incyte, and honoraria from Pfizer and Novartis. C.R. has received personal fees from AstraZeneca, Roche, Novartis, and Janssen. M.T. holds membership on the board of directors or advisory committees of Bristol Myers Squibb and Constellation Pharmaceuticals, has received research funding from Takeda and Novartis, and has been a consultant to IMAGO. M.M. has been a consultant to and has received honoraria, reimbursement of travel, accommodation and expenses, and research funding from Bristol Myers Squibb, Novartis, Takeda, and Pfizer, and research funding from Sun Pharma/SPARC. T.H. and V.L. are employees of Millennium Pharmaceuticals. S.S. is an employee of Takeda. M.D. is a consultant to, holds a membership on the board of directors or advisory committees of, was part of a study management committee of, and received research funding from Blueprint Medicines Corporation, is a consultant to Fusion Pharma, Medscape, and DisperSol, is a consultant to, has held membership on the board of directors or advisory committees of, and has received research funding from Takeda, is a consultant to and holds membership on the board of directors or advisory committee of Sangamo, is a consultant to and received research funding from Novartis, is a consultant to and received honoraria and research funding from Incyte, and has received research funding from SPARC, DisperSol, and the Leukemia and Lymphoma Society. C.P., A.T., C.K.A., J. M., and L.M. declare no competing financial interests., and Professional medical writing assistance was provided by Duprane Young of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, and funded by Millennium Pharmaceuticals, Inc.